FDA denies second approval for Theravance drug

Theravance said last Friday that the FDA had declined to provide an approval to use Telavancin for the treatment of nosocomial pneumonia, but hastened to add that it had already completed the extra analysis work that the FDA is seeking. Nevertheless, the developer adds that any approval will be delayed into 2010. Telavancin is already approved for skin infections. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.